These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15847764)

  • 1. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital setting.
    Cañas F; Ciudad A; Gutiérrez M; Gibert J; Gascón J; Carrasco JL; Bobes J; Gómez JC; Alvarez E
    Med Clin (Barc); 2005 Apr; 124(13):481-6. PubMed ID: 15847764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study.
    Ciudad A; Gutiérrez M; Cañas F; Gibert J; Gascón J; Carrasco JL; Bobes J; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):944-51. PubMed ID: 15950351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
    Bobes J; Gibert J; Ciudad A; Alvarez E; Cañas F; Carrasco JL; Gascón J; Gómez JC; Gutiérrez M
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):473-81. PubMed ID: 12691783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.
    Alvarez E; Bobes J; Gómez JC; Sacristán JA; Cañas F; Carrasco JL; Gascón J; Gibert J; Gutiérrez M;
    Eur Neuropsychopharmacol; 2003 Jan; 13(1):39-48. PubMed ID: 12480121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
    Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.
    Ciudad A; Montes JM; Olivares JM; Gómez JC;
    Eur Psychiatry; 2004 Sep; 19(6):358-65. PubMed ID: 15363475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.
    Molina JD; Toledo-Romero F; López-Rodríguez E; Amorin-Díaz M; Lerma-Carrillo I; López-Muñoz F
    Pharmacopsychiatry; 2011 Jun; 44(4):142-7. PubMed ID: 21710404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
    Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E
    J Clin Psychiatry; 2000 May; 61(5):335-43. PubMed ID: 10847307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.
    Castle DJ; Udristoiu T; Kim CY; Sarosi A; Pidrman V; Omar AN; Rosales JI; Melamed Y; Isik T; Karagianis J; Treuer T
    World J Biol Psychiatry; 2009; 10(1):43-53. PubMed ID: 19137460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.
    Carrasco JL; Gutiérrez M; Gómez JC; Escobar R; Alvarez E; Cañas F; Bobes J; Gascón J; Gibert J
    Int Clin Psychopharmacol; 2002 Nov; 17(6):287-95. PubMed ID: 12409682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.
    Chaichan W
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):364-8. PubMed ID: 15298648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.
    Dittmann RW; Meyer E; Freisleder FJ; Remschmidt H; Mehler-Wex C; Junghanss J; Hagenah U; Schulte-Markwort M; Poustka F; Schmidt MH; Schulz E; Mästele A; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):54-69. PubMed ID: 18294089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.